Patients randomized to the cooling arm (hypothermia) will be infused
with one liter of iced saline in addition to endovascular cooling and
patients assigned to the normothermia arm will receive routine standard
of care without induced hypothermia. Additional information about the
study can be found at http://www.clinicaltrials.gov.
-- Ongoing patient recruitment for the Company's Phase 3 Generx AWARE and
Phase 2b Excellarate MATRIX clinical trials. The AWARE clinical trial
is evaluating Generx as a potential treatment for myocardial ischemia
(insufficient blood flow within the heart muscle) which gives rise to
angina and is expected to enroll approximately 300 women at an
estimated 50 U.S. medical centers. Additional information about the
AWARE study can be found at http://www.cardiumthx.com/flash/aware.html.
The MATRIX clinical trial is evaluating the safety and efficacy of
Excellarate for the potential treatment of non-healing diabetic foot
ulcers and is expected to enroll approximately 210 patients at up to
40 U.S. sites. Additional information about the MATRIX study can be
found at http://www.t-r-co.com/images/Website_082407_(3).pdf.
-- Addition of Richard A. Schatz, M.D. to Cardium's Scientific Advisory
Board. Dr. Schatz is a pioneer of coronary stent technology and is
Research Director of Cardiovascular Interventions at the Heart, Lung,
and Vascular Center at Scripps Clinic in La Jolla, California.
-- Broadcast of the Science Channel's "Cool Stuff: How it Works" series
featuring the use of InnerCool's end
|SOURCE Cardium Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved